Campello E, Zabeo E, Radu CM, Spiezia L, Gavasso S, Fadin M, Woodhams B, Vettor R, Simioni P (2015) Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events
Medicare has long-been prohibited by law from covering medications used specifically for weight loss but covers GLP-1 drugs for other approved conditions like type 2 diabetes
Treatment plans are individualized based on facial anatomy and degree of volume loss, and multiple sessions may be recommended
Weight: 85 lb SDR: 10 to 15 mg/kg/day in 4 to 6 divided doses Ordered: 100 mg q6h 5
Obstetrics and Gynecology, 134(5), 899-908
It was the first study to report an association between GLP-1 and NAION The study divided patients with type 2 diabetes or who were overweight/obese into groups based on whether they were prescribed a GLP-1 medication or non-GLP-1 RA medications